2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Fulvestrant
19
Letrozole
10
Anastrozole
8
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Injections
4
Goserelin
4
Docetaxel
4
trastuzumab deruxtecan
3
pyrotinib
3
exemestane
3
Vinorelbine
3
Aromatase Inhibitors
3
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
dalpiciclib
2
abemaciclib
2
Trastuzumab
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
AZD9833
×
Clear all
NCT07427394
2026-05-28
SERENA-1b
AstraZeneca
Phase 2
Recruiting
24 enrolled
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled